BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 18394702)

  • 1. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
    Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
    Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
    Kim KT; Levis M; Small D
    Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
    Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Udaka K; Yokoyama A
    Leuk Res; 2011 Jul; 35(7):932-9. PubMed ID: 21550660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
    Nishioka C; Ikezoe T; Yang J; Takeshita A; Taniguchi A; Komatsu N; Togitani K; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Jun; 32(6):865-72. PubMed ID: 17983653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
    Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
    Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
    Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
    Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
    Reikvam H; Hatfield KJ; Ersvaer E; Hovland R; Skavland J; Gjertsen BT; Petersen K; Bruserud O
    Br J Haematol; 2012 Feb; 156(4):468-80. PubMed ID: 22150087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
    George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
    Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q; Nishiuchi R; Kitamura T; Kersey JH
    Leukemia; 2005 Sep; 19(9):1605-12. PubMed ID: 16034464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
    Lopes de Menezes DE; Peng J; Garrett EN; Louie SG; Lee SH; Wiesmann M; Tang Y; Shephard L; Goldbeck C; Oei Y; Ye H; Aukerman SL; Heise C
    Clin Cancer Res; 2005 Jul; 11(14):5281-91. PubMed ID: 16033847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
    Ota H; Tokunaga E; Chang K; Hikasa M; Iijima K; Eto M; Kozaki K; Akishita M; Ouchi Y; Kaneki M
    Oncogene; 2006 Jan; 25(2):176-85. PubMed ID: 16170353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.
    Masson K; Liu T; Khan R; Sun J; Rönnstrand L
    Br J Haematol; 2009 Jul; 146(2):193-202. PubMed ID: 19438505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.
    Scholl S; Müller R; Clement JH; Loncarevic IF; Böhmer FD; Höffken K
    Leuk Res; 2006 May; 30(5):633-42. PubMed ID: 16473406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3-ITD expression levels and their effect on STAT5 in AML with and without NPM mutations.
    Seedhouse CH; Pallis M; Grundy M; Shang S; Russell NH
    Br J Haematol; 2009 Dec; 147(5):653-61. PubMed ID: 19775300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.